Discontinued — last reported Q3 '20
Eli Lilly Available-for-Sale Debt Securities - Fair Value (Maturing 1 to 5 Years) decreased by 40.9% to $119.40M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 35.5%, from $185.10M to $119.40M.
afs_debt_securities_fair_value_maturing_1_to_5y| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $163.90M | $157.80M | $197.70M | $170.40M | $197.80M | $219.40M | $213.20M | $201.60M | $222.40M | $185.70M | $185.10M | $171.00M | $201.90M | $119.40M |
| QoQ Change | — | -3.7% | +25.3% | -13.8% | +16.1% | +10.9% | -2.8% | -5.4% | +10.3% | -16.5% | -0.3% | -7.6% | +18.1% | -40.9% |
| YoY Change | — | — | — | +4.0% | +25.3% | +11.0% | +25.1% | +1.9% | +1.4% | -12.9% | -8.2% | -23.1% | +8.7% | -35.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.